Abstract 2087
Background
The aim of this study was to determine the effect of e-mobile education on the quality of life of women diagnosed with breast cancer who received endocrine hormone therapy.
Methods
The study was conducted as a randomized controlled study between January and July 2018 in the Medical Oncology Outpatient Clinic of a state hospital in the province of Turkey.A total of 64 patients were included in the study according to the inclusion criteria of randomization, split into treatment (n = 31) and control group (n = 33).Data were collected using Patient Introductory Information Form, FACT-ES Quality of Life Scale and NCCN Distress Thermometer.The data were collected twice during the first week of the study and 12th week at the end of the study by face-to-face and/or telephone interviews.Treatment group patients were received information via mobile application for three months during which they were contacted in every 15 days; e-mobile training was provided, including information about breast cancer definition, treatment process, symptoms experienced during endocrine hormone therapy, adequate nutrition, regular physical activity and coping with stress.
Results
The mean total quality of life after e-mobile training to the treatment group was found to be significantly higher than the control group, and the mean distress score was lower than the control group (p < 0.05).For quality of life subscales of patients in the e-mobile training and treatment group; the scores of physical well-being, emotional well-being and endocrine symptoms were found to be significantly higher than the control group (p < 0.05).There was found no difference between the mean scores of social / family well-being subscale scores of the patients in the e-mobile training and treatment group and the control group.Treatment group reported that e-mobile training was “informative and useful a training” (87.1%).
Conclusions
As a result of the study, it has been concluded the quality of life of the patients increased when nurses use the e-mobile training and counseling in order to manage the disease process and symptoms of the women diagnosed with breast cancer and who are receiving endocrine hormone therapy with the help of the developing technologies and using the mobile technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract